Diabetes Medicine

Product Details:

Semaglutide 1.7 mg is a once-weekly injectable medication used as part of a weight management treatment plan. It belongs to the GLP-1 receptor agonist class and is the second-to-last step in the dose escalation schedule for patients using Semaglutide for obesity or overweight with weight-related health conditions (e.g., high blood pressure, type 2 diabetes, or high cholesterol).

This dose is commonly associated with Wegovy (a brand of Semaglutide approved for chronic weight management) and is prescribed after patients tolerate lower doses like 0.25 mg, 0.5 mg, and 1.0 mg.

How It Works:
Semaglutide mimics the GLP-1 hormone to:

• Reduce appetite and cravings

• Slow digestion and promote early satiety

• Regulate blood sugar and insulin levels

• Support consistent, sustainable weight loss

Administration:

• Subcutaneous injection once per week

• Can be injected into the abdomen, thigh, or upper arm

• Provided in a prefilled pen, easy to use at home

Who It’s For:

• Adults with a BMI ≥30 (obese), or ≥27 (overweight) with a weight-related medical condition

• Patients who have successfully completed the dose escalation process

• Individuals under the care of a licensed healthcare provider for long-term weight management

Key Benefits:

• Significant weight loss support when paired with diet and physical activity

• Helps control appetite and reduce caloric intake

• May improve metabolic health markers (blood sugar, cholesterol, blood pressure)

Semaglutide 1.7 mg is primarily used as part of a medical weight loss plan. It’s one of the final dose steps before reaching the full 2.4 mg maintenance dose used in Wegovy.

Yes, Semaglutide is FDA-approved for chronic weight management under the Wegovy brand. The 1.7 mg dose is part of the stepwise titration required to safely reach the full 2.4 mg dose.

Gradual dose escalation (starting at 0.25 mg) helps your body adjust and minimizes side effects like nausea or stomach discomfort.

Once per week, on the same day each week, with or without food.

It is typically a step toward the full 2.4 mg maintenance dose, but some patients may remain on 1.7 mg if they experience good results or cannot tolerate higher doses. Your doctor will advise what’s best for you.

Common side effects include:

• Nausea

• Vomiting

• Diarrhea or constipation

• Headache

• Decreased appetite

• Fatigue

These often lessen over time or with dose adjustments.

It is injected under the skin using a prefilled pen. The injection is quick and can be done at home after proper training.

• Unused pens: Refrigerate at 36°F to 46°F (2°C to 8°C)

• In-use pens: May be kept at room temperature (below 86°F or 30°C) for up to 56 days

A balanced, reduced-calorie diet and increased physical activity are recommended for best results. Your provider or a nutritionist may give you personalized guidance.

Product Details:

Semaglutide 1.7 mg is a once-weekly injectable medication used as part of a weight management treatment plan. It belongs to the GLP-1 receptor agonist class and is the second-to-last step in the dose escalation schedule for patients using Semaglutide for obesity or overweight with weight-related health conditions (e.g., high blood pressure, type 2 diabetes, or high cholesterol).

This dose is commonly associated with Wegovy (a brand of Semaglutide approved for chronic weight management) and is prescribed after patients tolerate lower doses like 0.25 mg, 0.5 mg, and 1.0 mg.

How It Works:
Semaglutide mimics the GLP-1 hormone to:

• Reduce appetite and cravings

• Slow digestion and promote early satiety

• Regulate blood sugar and insulin levels

• Support consistent, sustainable weight loss

Administration:

• Subcutaneous injection once per week

• Can be injected into the abdomen, thigh, or upper arm

• Provided in a prefilled pen, easy to use at home

Who It’s For:

• Adults with a BMI ≥30 (obese), or ≥27 (overweight) with a weight-related medical condition

• Patients who have successfully completed the dose escalation process

• Individuals under the care of a licensed healthcare provider for long-term weight management

Key Benefits:

• Significant weight loss support when paired with diet and physical activity

• Helps control appetite and reduce caloric intake

• May improve metabolic health markers (blood sugar, cholesterol, blood pressure)

Semaglutide 1.7 mg is primarily used as part of a medical weight loss plan. It’s one of the final dose steps before reaching the full 2.4 mg maintenance dose used in Wegovy.

Yes, Semaglutide is FDA-approved for chronic weight management under the Wegovy brand. The 1.7 mg dose is part of the stepwise titration required to safely reach the full 2.4 mg dose.

Gradual dose escalation (starting at 0.25 mg) helps your body adjust and minimizes side effects like nausea or stomach discomfort.

Once per week, on the same day each week, with or without food.

It is typically a step toward the full 2.4 mg maintenance dose, but some patients may remain on 1.7 mg if they experience good results or cannot tolerate higher doses. Your doctor will advise what’s best for you.

Common side effects include:

• Nausea

• Vomiting

• Diarrhea or constipation

• Headache

• Decreased appetite

• Fatigue

These often lessen over time or with dose adjustments.

It is injected under the skin using a prefilled pen. The injection is quick and can be done at home after proper training.

• Unused pens: Refrigerate at 36°F to 46°F (2°C to 8°C)

• In-use pens: May be kept at room temperature (below 86°F or 30°C) for up to 56 days

A balanced, reduced-calorie diet and increased physical activity are recommended for best results. Your provider or a nutritionist may give you personalized guidance.